The Global Burden of Early-Onset Pancreatic Cancer and Its Risk Factors: A Perspective From Global Burden of Disease Study 2019.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
Despite evidence of increased incidence of early-onset pancreatic cancer (EOPC), defined as pancreatic cancer diagnosed in patients below 50 years old, and its risk factors in the Western region, global epidemiological data addressing this issue is still lacking. Utilizing data from the Global Burden of Disease Study 2019, we aimed to conduct a comprehensive analysis of the incidence, deaths, and disability-adjusted life years (DALYs) associated with EOPC and its risk factors, including smoking, obesity, and diabetes. The analysis examined the annual percentage change (APC) over the period. In 2019, the incidence of EOPC surpassed 35,000 cases worldwide. This burden of EOPC tends to be more prevalent in males, as well as in Europe and high SDI countries. However, there is a noticeable upward trend in the burden of EOPC in the Eastern Mediterranean. While there is a global decline in EOPC mortality attributed to smoking (APC -0.33%), there is a concerning increase in mortality associated with diabetes (APC +2.84%) and obesity (APC +2.12%). The burden of EOPC has been increasing. The mortality is rising mainly from metabolic factors. There is an urgent need for national policy development for reducing the burden of this disease.
Identifiants
pubmed: 38530945
doi: 10.1097/MPA.0000000000002331
pii: 00006676-990000000-00137
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interests: Michael B. Wallace declared the conflict of interest as designated below: Conflict of Interests
Références
Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27.
Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851–862.
Li Q, Feng Z, Miao R, et al. Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution. World J Surg Oncol. 2022;20:11.
Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395:2008–2020.
Wang S, Zheng Y, Yang F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6:249.
Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209.
Saadat LV, Chou JF, Gonen M, et al. Treatment patterns and survival in patients with early-onset pancreatic cancer. Cancer. 2021;127:3566–3578.
Ansari D, Althini C, Ohlsson H, et al. Early-onset pancreatic cancer: a population-based study using the SEER registry. Langenbecks Arch Surg. 2019;404:565–571.
Takeda T, Sasaki T, Inoue Y, et al. Early-onset pancreatic cancer: clinical characteristics and survival outcomes. Pancreatology. 2022;22:507–515.
Abboud Y, Samaan JS, Oh J, et al. Increasing pancreatic cancer incidence in young women in the United States: a population-based time-trend analysis, 2001–2018. Gastroenterology. 2023;164:978–89.e6.
LaPelusa M, Shen C, Arhin ND, et al. Trends in the incidence and treatment of early-onset pancreatic cancer. Cancers (Basel, 2022;14:283.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222.
Ulanja MB, Moody AE, Beutler BD, et al. Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. Oncotarget. 2022;13:828–841.
GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4:934–947.
Liang R, Feng X, Shi D, et al. The global burden of disease attributable to high fasting plasma glucose in 204 countries and territories, 1990–2019: an updated analysis for the Global Burden of Disease Study 2019. Diabetes Metab Res Rev. 2022;38:e3572.
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223–1249.
GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021;397:2337–2360.
Chew NWS, Ng CH, Tan DJH, et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 2023;35:414–28.e3.
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20:12.
Lykoudis PM, Contis J. Estrogen receptor expression in pancreatic adenocarcinoma: time to reconsider evidence. Pancreas. 2021;50:1250–1253.
Idachaba S, Dada O, Abimbola O, et al. A review of pancreatic cancer: epidemiology, genetics, screening, and management. Open Access Maced J Med Sci. 2019;7:663–671.
Jiang W, Xiang C, Du Y, et al. The Global, Regional and National Burden of Pancreatic Cancer Attributable to Smoking, 1990 to 2019: a systematic analysis from the Global Burden of Disease Study 2019. Int J Environ Res Public Health. 2023;20:1552.
Chen DY, Yang XY, Fan WL, et al. Analysis and forecast of burden of pancreatic cancer along with attributable risk factors in Asia countries between 1990 and 2019 [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2022;44:955–961.
Ntala C, Debernardi S, Feakins RM, et al. Demographic, clinical, and pathological features of early onset pancreatic cancer patients. BMC Gastroenterol. 2018;18:139.
Lin RT, Chen PL, Yang CY, et al. Risk factors related to age at diagnosis of pancreatic cancer: a retrospective cohort pilot study. BMC Gastroenterol. 2022;22:243.
Nodari Y, Gentiluomo M, Mohelnikova-Duchonova B, et al. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Dig Liver Dis. 2023;55:1417–1425.
Hartwig W, Büchler MW. Pancreatic cancer: current options for diagnosis, staging and therapeutic management. Gastrointest Tumors. 2013;1:41–52.